10x Genomics delivered strong Q4 2023 results with substantial contributions from Xenium and Visium platforms. As the company enters 2024, its focus on expanding product adoption while managing ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

10x Genomics platforms like Chromium, Visium, and Xenium aid in single-cell and spatial . Recently, 10x Genomics rolled out new products like the Xenium Prime 5K for cell and tissue analysis.

These capabilities will be available to support both the Chromium and Visium platforms ... tissue organization and function. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable ...

10x Genomics, Inc., a life science technology ... of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve ...

The company also highlighted Visium HD XL, which will feature an expanded capture area to enable whole transcriptome spatial gene expression analysis of larger tissue sections at single-cell-scale ...

The forthcoming Visium HD 3' assay is a reverse transcription ... sections at single-cell-scale resolution. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable simultaneous ...